Gilead Sciences
GILD · NASDAQ
Bulios Fair Price
$82.37
42.7% downside
Current Price
$143.72
According to Bulios Fair Price, GILD is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Gilead Sciences, Inc. (GILD) is an American biopharmaceutical company specializing in research, development, and manufacturing of pharmaceuticals in the field of infectious diseases, viral diseases, and chronic conditions, such as HIV/AIDS, hepatitis C, hepatitis B, and more. The company is renowned for its innovative treatment approaches and drugs that have a significant impact on improving the quality of life for patients worldwide. Gilead Sciences is actively engaged in research and collaborates with academic institutions and healthcare organizations to discover new therapies and medications. With successful products and a strong research background, Gilead Sciences, Inc. has the potential for further innovations and expanding its pharmaceutical portfolio. Investing in Gilead Sciences, Inc. (GILD) shares may present an interesting choice for investors who follow the pharmaceutical sector and seek a company with a track record of successful products and commitment to combating serious diseases.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Daniel O'Day
Employees
17,000
Headquarters
Foster City
Upcoming events
Ex-Dividend
Ex-dividend date
Dividend Payment
Payment date
Earnings
Upcoming earnings report